CRITICARE SYSTEMS INC /DE/ Form DEFA14A October 19, 2006

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Pursuant to § 240.14a-12

CRITICARE SYSTEMS, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

- (1) Title of each class of securities to which transaction applies:
- (2) Aggregate number of securities to which transaction applies:
- (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
- (4) Proposed maximum aggregate value of transaction:
- (5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

(2) Form, schedule or registration statement no.:	
(3) Filing party:	
(4) Date filed:	

FOR IMMEDIATE RELEASE


Contact: Emil Soika, President and CEO Criticare (262) 798-8282

Criticare Systems, Inc. Reports Strong Revenue Growth for First Quarter of Fiscal 2007

MILWAUKEE--(BUSINESS WIRE) October 19, 2006--CRITICARE SYSTEMS, INC. (AMEX:CMD_News). Criticare Systems Inc. today announced its unaudited first quarter revenue for fiscal 2007.

The company recorded revenue of approximately \$8.1 million compared to \$7.6 million for the comparable period in fiscal 2006. Revenue for the fourth quarter of fiscal 2006 was \$7.1 million. Sales were particularly strong in Criticare s domestic initiatives as well as efforts in Latin America. A major success was seen with the company s new Acute Care monitoring line and the nGenuity, which was introduced this past May. This product line offers many innovative features, at a very attractive acquisition cost, raising the bar for an economic solution.

Thanks in part to the introductory relationship with Kodak Dental, Criticare experienced record sales during the annual Oral and Maxillofacial Surgery convention, held on October 5, 6 and 7 at the San Diego convention center. Traditionally, this has been Criticares most productive convention, both in terms of orders taken during the convention



Information regarding the identity of the persons who under SEC rules may be deemed to be participants in the solicitation by the Company s of its stockholders in connection with this consent solicitation, and the participants interests in the solicitation, are set forth in the Company s definitive consent revocation statement.

If you have any questions or need any information concerning this solicitation and our consent revocation, please contact: The Altman Group, toll free at (800) 283-3192.